Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Lawrence Recht
- Target Recruit Count
- 30
- Registration Number
- NCT01977677
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 39
- Registration Number
- NCT01954914
- Locations
- 🇩🇪
Cellex Gesellschaft für Zellgewinnung mbH Dresden, Dresden, Germany
🇩🇪Universitätsklinikum Dresden, Medizinische Klinik I, Dresden, Germany
🇩🇪Cellex Gesellschaft für Zellgewinnung mbH Köln, Köln, Germany
Plerixafor for Stem Cell Mobilization in Normal Donors
- Conditions
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01818284
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01802892
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01767714
- Locations
- 🇨🇳
Investigational Site Number 156001, Beijing, China
🇨🇳Investigational Site Number 156003, Beijing, China
🇨🇳Investigational Site Number 156020, Chongqing, China
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT01753453
- Locations
- 🇧🇪
Investigational Site Number 056002, Brugge, Belgium
🇱🇹Investigational Site Number 440001, Vilnius, Lithuania
🇪🇪Investigational Site Number 233001, Tallinn, Estonia
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01746173
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
- Conditions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 262
- Registration Number
- NCT01738373
Prospective Observational Study on Plerixafor After Chemotherapy
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2012-10-04
- Target Recruit Count
- 27
- Registration Number
- NCT01700608
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
- Conditions
- Interventions
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 127
- Registration Number
- NCT01696461
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.